Mechanisms of severe cutaneous adverse reactions: recent advances

T Bellón - Drug safety, 2019 - Springer
Cutaneous adverse drug reactions are unpredictable and include various different skin
conditions of varying degrees of severity. The most concerning are usually referred to as …

[HTML][HTML] Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis

L Lucia, C Silvia, B Paolo, B Roberto… - Acta Bio Medica …, 2019 - ncbi.nlm.nih.gov
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be
considered a late-onset allergic reaction, can cause serious long-term sequelae. SJS/TEN …

British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018

T McPherson, LS Exton, S Biswas… - British Journal of …, 2019 - academic.oup.com
British Association of Dermatologists' guidelines for the management of Stevens–Johnson
syndrome/toxic epidermal necrolysis in children and young people, 2018 | British Journal of …

Identification of drug-specific public TCR driving severe cutaneous adverse reactions

RY Pan, MT Chu, CW Wang, YS Lee… - Nature …, 2019 - nature.com
Drug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life …

Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population‐based cohort study and meta‐analysis

CH Chen, CB Chen, CJ Chang, YJ Lin… - Clinical …, 2019 - Wiley Online Library
The safety of newer xanthine oxidase inhibitor febuxostat compared to allopurinol remains
unclear. To compare the risks of allopurinol hypersensitivity and febuxostat hypersensitivity …

Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions

JH Karnes, MA Miller, KD White… - Annual review of …, 2019 - annualreviews.org
Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated
adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a …

Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis

CH Pham, TJ Gillenwater, E Nagengast… - Burns, 2019 - Elsevier
Abstract Background Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is
an autoimmune condition with significant morbidity and mortality. Methods A retrospective …

Learning from success and failure: biologics for non-approved skin diseases

R Speeckaert, J Lambert, N Van Geel - Frontiers in Immunology, 2019 - frontiersin.org
The impressive potential of biologics has been demonstrated in psoriasis, hidradenitis
suppurativa, and urticaria. Numerous biologicals are entering the field for a restricted …

Rapid remission of Stevens–Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature

R Wang, S Zhong, P Tu, R Li, M Wang - Dermatologic Therapy, 2019 - Wiley Online Library
Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are spectrum of rare,
acute, and life‐threatening delayed‐type drug hypersensitivity reactions that are associated …

Association of early systemic corticosteroid therapy with mortality in patients with Stevens–Johnson syndrome or toxic epidermal necrolysis: a retrospective cohort …

K Morita, H Matsui, N Michihata, K Fushimi… - American Journal of …, 2019 - Springer
Abstract Background Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are severe dermatologic disorders with high mortality. The role of systemic …